■他莫昔芬已成功用作乳腺癌的辅助疗法。然而,他莫昔芬作为雌激素激动剂和拮抗剂的作用可引起子宫的病理变化。激动剂效应可能刺激子宫内膜增殖,导致子宫内膜息肉,增生,and,很少,子宫内膜癌.
■我们介绍了他莫昔芬治疗的乳腺癌病例,以更好地了解最严重的后果之一,子宫内膜癌.
一名37岁的妇女因阴道异常出血而来到我们中心。她在2018年被诊断为I级浸润性导管癌,主要主诉为右乳腺肿块和腋窝淋巴结肿大。在此期间,辅助化疗给予他莫昔芬20mg,每日1次.在为期三年的六个月的随访中,没有投诉或复发。第四年,患者主诉阴道出血。进行了阴道活检,结果显示为低级别子宫内膜样型子宫内膜癌。进行了全子宫切除术和双侧输卵管卵巢切除术,结果多达一半的子宫肌层内膜肿块,并伴有转移性负视差淋巴结。
■他莫昔芬治疗后,患者更容易发生子宫内膜癌。经历不规则阴道出血的患者应进行宫腔镜检查或子宫超声检查,如果原因不明,应该进行活检。
UNASSIGNED: Tamoxifen has been successfully administered as adjunctive therapy for breast cancer. However, the effect of
tamoxifen as an estrogen agonist and antagonist can cause pathological changes in the uterus. The agonist effect may stimulate endometrial proliferation leading to endometrial polyps, hyperplasia, and, rarely, endometrial cancer.
UNASSIGNED: We present the
case of
tamoxifen-treated breast cancer
case to better understand one of the most serious consequences, endometrial cancer.
UNASSIGNED: A 37-year-old woman came to our centre with complaints of abnormal vaginal bleeding. She has diagnosed with grade I infiltrative ductal carcinoma in 2018, with primary complaints of right breast mass and axillary lymphadenopathy. During this period, adjuvant chemotherapy was given
tamoxifen 20 mg once daily. There were no complaints or relapses at a six-month follow-up over three years. In the fourth year, the patient complained of vaginal bleeding. A vaginal biopsy was performed, and the results showed low-grade endometrioid-type endometrial carcinoma. Total hysterectomy and bilateral salpingo-oophorectomy were performed with the resultant mass of up to half of the myometrial lining with metastatic negative parallax lymph nodes.
UNASSIGNED: Following
tamoxifen therapy, endometrial cancer is more likely to occur in patients. Patients who experience irregular vaginal hemorrhage should have hysteroscopy or uterine ultrasound performed, and if the cause is unknown, a biopsy should be performed.